article · LUTS Lower Urinary Tract Symptoms
Infection with COVID-19 significantly worsens lower urinary tract symptoms in men with benign prostatic hyperplasia. This infection results in an increase in the International Prostate Symptom Score, which in turn leads to changes in the treatment approaches required for managing benign prostatic hyperplasia. Furthermore, multivariate analysis identifies age, the baseline International Prostate Symptom Score prior to contracting the virus, and a positive urine culture as independent predictors of subsequent urine retention following COVID-19 infection.
Understanding how viral infections influence pre-existing conditions helps healthcare providers anticipate complications. Identifying that COVID-19 worsens urinary symptoms and can trigger urine retention allows clinicians to recognise high-risk patients earlier. This ensures that vulnerable individuals with benign prostatic hyperplasia receive timely treatment adjustments to prevent severe urinary complications.
The findings provide clinical evidence that could inform risk-stratification protocols or clinical decision-support tools for urology practices managing patients recovering from viral infections. Potential users include hospital urology departments and primary care clinicians. However, because this is early-stage observational research, the abstract does not indicate a direct pathway to a commercial product.
AI-generated from the published abstract. Always read the original work before citing.
LUTS in BPH patients were significantly affected by COVID-19. COVID-19 increases IPSS leading to a change in the treatment modality of BPH. On multivariate analysis, age, pre-COVID-19 IPSS, and positive urine culture were the independent predictors of urine retention post COVID-19 infection.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1111/luts.12407
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
